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Abstract
Background: Tuberculosis (TB)-associated Immune reconstitution inflammatory syndrome (TB-IRIS) is an aberrant
inflammatory response in TB patients with advanced human immunodeficiency virus coinfection, after antiretroviral
therapy commencement.
Case presentation: We present a rare case of a 51-year-old woman living with HIV who developed a series of TB-
IRIS events occurring at multiple sites sequentially, highlighting the clinical complexity in diagnosis and
management.
Conclusion: This case illustrates how complicated a clinical scenario of successive TB-IRIS episodes can be, in terms
of clinical management.
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Background
Immune reconstitution inflammatory syndrome (IRIS)
poses important challenges in the clinical management
of HIV-TB patients initiating antiretroviral therapy
(ART). In HIV patients with TB, IRIS is thought to occur
in two distinct scenarios. First, unmasking of a previously
undiagnosed TB infection prior to ART initiation. Alter-
natively, paradoxical clinical or radiological worsening of
TB in patients previously improving with antituberculous
treatment (ATT) following ART introduction and despite
effective virological suppression [1]. The pathogenesis of
IRIS remains incompletely understood. The most signifi-
cant event leading to TB-IRIS in HIV is failure of the im-
mune system to eliminate Mycobacterium tuberculosis,
causing high mycobacterial burden in those with severe
immunosuppression and lymphopenia prior to ART,
followed by its restitution and immune activation [2].
Contrary to the belief that IRIS is a rare condition, a re-
cent meta-analysis demonstrated a pooled estimated inci-
dence of up to 18% among HIV-associated TB initiating
ART [3]. Here, we present a rare case of both unmasking
and paradoxical TB-IRIS occurring at multiple sites se-
quentially, highlighting the clinical complexity in diagnosis
and management.
Case presentation
An asymptomatic 51-year-old woman without significant
past medical history was diagnosed with HIV-1 infection
on April 06, 2010 after her spouse died of HIV. Her
baseline Chest X-ray was reported as normal and phys-
ical examination did not revealed any relevant clinical
signs. She presented with a CD4+ T-cell count of 51
cells/μL and HIV viral load of 5.8 log10 copies/mL. ART
was initiated with stavudine, lamivudine and nevirapine
as per Indian National guidelines [4]. After 32 days on
ART, she presented a clinical deterioration, with cough,
afternoon fever, weight loss and night sweat, symptoms
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suggestive of pulmonary TB and subsequently confirmed
to be drug-sensitive M. tuberculosis by sputum smear
and culture (Fig. 1a). Standard ATT was started with
Isoniazid, Rifampicin, Ethambutol, Pyrazinamide on May
08, 2010 (Fig. 1a) with nevirapine substituted for efavir-
enz. Repeat laboratory results revealed a CD4+ T-cell
count of 146 cells/μL and viral load of < 2log10 copies/
mL (400 copies/mL) (Fig. 1b). A panel of independent
physicians reviewed the patient’s history, radiographs
and physical examination. This independent panel of cli-
nicians used the INSHI definition of unmasking TB IRIS
[5], composed by the following criteria: not receiving TB
treatment at ART initiation; diagnosis of active TB after
ART initiation; fulfilling WHO diagnostic criteria for
TB; presentation within 3 months of ART initiation and
heightened intensity of clinical manifestations once on
TB treatment. The panel concluded that the patient had
unmasking TB-IRIS at ART initiation.
After 48 days since ATT and efavirenz based ART were
initiated, the patient presented with generalized pruritus
and strong vague abdominal pain. Physical examination
revealed fever, jaundice and left sided cervical lymph-
adenopathy. Laboratory tests were notable for high levels
of total bilirubin 8.3mg/dL (reference value [RV]: 0.2–1.0
mg/dL) with increases in aspartate aminotransferase AST,
72U/L (RV: 5.0–40.0 U/L) and alanine aminotransferase
ALT, 59U/L (RV: 7.0–56.0 U/L). Abdominal ultrasound
revealed enlargement and obstruction of the porta hepatis
by periportal nodes with normal echotexture of the liver
and gall bladder. At this crisis, ATT was modified to
Fig. 1 Multifocal TB-IRIS: timeline of events. a Timeline of the clinical evolution show the temporal relationship between IRIS events with time on
ART and ATT. Colored boxes indicated distinct clinical events with the respective radiological examination. b CD4+ T-cell count and viral load in
each IRIS clinical episode
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streptomycin, ofloxacin and ethambutol, second-line ther-
apy (Fig. 1a), and ART was temporarily withheld, follow-
ing advice from the panel of physicians reviewed, due to
potential ART-induced liver toxicity. On July 19, 2010,
with the liver function tests returning to normal (Table 1),
standard ATT regimen was re-introduced. After 11 days,
ART was reinitiated as the HIV viral load was > 5.9log10-
copies/mL (Fig. 1b).
One week after ART reintroduction, the patient devel-
oped rapid clinical deterioration with focal complex par-
tial convulsions prompting initiation of anticonvulsant
therapy. Brain Computational Tomography (CT) scan
revealed a frontoparietal space occupying lesion with
peri-lesional, edema suggestive of tuberculoma (Fig. 1a).
Following the CT scan results, cerebral spinal fluid was
collected, and results excluded other potential opportun-
istic infections, such as neurocryptococcosis or toxoplas-
mosis. ART was again withheld temporarily while
continuing ATT, because the independent clinical panel
suggested the possibility of severe central nervous sys-
tem (CNS) IRIS. Initially, she was treated with intraven-
ous steroids and mannitol followed by acetazolamide to
reduce perilesional edema. Oral prednisolone was grad-
ually tapered over 8 weeks. Laboratory investigations
demonstrated CD4+ T-cell count of 178cells/μL and
HIV viral load of 2.83 log10 copies/mL. The patient re-
covered after 6 weeks, only to have a viral rebound (HIV
viral load of 5.3 log10 copies/mL) (Fig. 1b). It was de-
cided to reintroduce ART as an inpatient with stringent
clinical monitoring while on oral steroids (Fig. 1a). In
November 29, 2010, a repeat brain CT scan showed re-
gression and calcification of the lesion. ATT was stopped
on December 6, 2010 (total of 8-month duration) while
ART and anticonvulsants were continued based on a
consensus opinion from IRIS experts, TB experts and
neurologists.
In May 2011, 5 months after completing ATT, the pa-
tient developed a swelling in the left iliac region. X-ray
and CT of the spine were normal while ultrasonogram
identified a localized intramuscular abscess which was
drained under guidance, and the aspirate was negative
for acid-fast bacilli (AFB) in smear and cultures for
mycobacteria and gram positive or negative bacteria, as
well as fungi. Laboratory tests results showed CD4+ T-
cell count of 323 cells/μL and HIV viral load < 2 log10
copies/mL (Fig. 1b). Other laboratory exams were nor-
mal (Table 1). Repeat CT scan of the brain showed fur-
ther regression and calcification of the tuberculoma.
Thereafter, the patient remained clinically asymptomatic
and was followed for 30 months. Smears and cultures 30
months post ATT treatment were all negative after she
converted in the first month and viral loads were sup-
pressed as well.
Discussion and conclusion
TB-IRIS is an exaggerated, dysregulated response against
M. tuberculosis that frequently occurs after initiation of
ART despite effective suppression of HIV viremia and a
temporal improvement with ATT [6]. TB-IRIS is a com-
mon phenomenon in HIV-TB coinfected patients, ran-
ging from 2% [7] to 54% [8] depending on predisposing
factors, such as the degree of immunological suppression
prior to ART [2] and the presence of disseminated
disease. It is thought that poor immunity against M. tu-
berculosis in highly immunosuppressed HIV+ patients
results in delayed clearance of the opportunistic patho-
gen leading to elevated mycobacterial load and dissemin-
ation of infection [1]. Once there is CD4+ T-cell
recovery, followed by restoration of immune responses,
hyper activation of infected macrophages and dendritic
cells leads to increased production and release of pro-
inflammatory mediators such as interleukin (IL)-1β, IL-6
Table 1 Plasma measurements according to date of assessment
Date 05.14.10 06.25.10 07.16.10 07.27.10 08.03.10 09.14.10 11.29.10 5.29.11
Hb (g/dL) 7.6 10.7 10.2 11.3 12.2 13.3
RBC (Cells/mm3) 2.93 3.75 3.47 4.15 4.32 4.15
WBC (Cells/mm3) 10,600 5600 7900 9100 8700 9200
Platelets(× 103/mm3) 543 365 464 285 386 544
CD4 (Cells/mm3) 146 116 178 58 140 323
CD8(Cells/mm3) 386 662 441 593 778 1466
Viral Load (Log10copies/mL) < 2 > 6 2.83 5.3 < 2 < 2
Direct Bilirubin (mg/dL) 0.6 8.3 2 2.7 1.2 0.4 0.4
AST (IU/L) 65 72 36 125 30 29 27
ALT (IU/L) 63 59 27 61 23 22 21
ALT alanine aminotransferase, AST aspartate aminotransferase, Hb hemoglobin, RBC red blood cells, WBC white blood cells
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and IL-18 at infection sites [1]. Such hypercytokinaemia
[9] is a hallmark of TB-IRIS. The case presented here ex-
hibited multiple IRIS episodes, or late TB-IRIS onset [10,
11] which posed challenges in clinical management.
Multifocal TB-IRIS is uncommon. Our main hypothesis
is that our patient was highly immunosuppressed as
reflected by her CD4+ T-cell count, and thus had myco-
bacterial dissemination to several different sites. We
have recently reported that presence of extrapulmonary
TB is linked to increased odds of TB-IRIS in a South In-
dian cohort, but a logistic regression model adjusted for
other factors such as CD4+ T-cell counts and HIV viral
load resulted in loss of significance [12], probably because
these variables are highly associated with each other. In
the case presented here, the restoration of immunity fol-
lowing ART caused a series of inflammatory perturbations
with accompanying episodes of clinical deterioration oc-
curring in specific infection sites. Compartmentalization
of immune responses/reconstitution could also explain
the distinct events affecting different locations.
The bacillary loads and risk of infection dissemination
are usually high in patients with advanced HIV infection
[13]. Perhaps for this reason the patient could have ini-
tially presented with unmasking pulmonary TB. The
hepatic portal event, occurring in the first 4 weeks, may
have also been a consequence of rapid immune-
mediated mycobacterial clearance associated with a high
bacillary load at the affected site prior to immune recon-
stitution. With ATT modification and ART withdraw, im-
mune recovery decreased its pace and liver profile was
restored. The new neurological presentation after re-
initiation of ART could be caused by at least two distinct
mechanisms: (i) there was a HIV viral load rebound subse-
quent to stopping ART and then re-starting ART, which
could have increased risk of paradoxical TB-IRIS-like
phenomenon; (ii) it is possible that the revised TB regi-
men after the hepatic porta event had poor central ner-
vous system penetration and that for this reason
disseminated TB has progressed at this site. With reestab-
lishment of high microbial burden at the time of ART re-
introduction, again an exaggerated and dysregulated
immune response occurred, and at this time in the brain,
leading to focal seizures with CT imaging consistent with
tuberculoma. This latter event had a critical and rapid de-
terioration of clinical symptoms (severe IRIS episode),
leading to a new withdraw of ART. Again, with ART sus-
pended, the exaggerated response declined, allowing clin-
ical stability. Lastly, several months after ATT, the patient
probably had cleared or highly reduced mycobacterial
loads, which potentially were still not able to prevent oc-
currence of the last episode of abscess in the left iliac
fossa. This case illustrates how complicated a clinical sce-
nario of successive TB-IRIS episodes can be, in terms of
clinical management. The complexity associated with
rapid clinical deterioration, and oscillation of clinical sta-
tus between IRIS episodes, makes the therapeutic manage-
ment a relevant challenge. The ART interruption,
observed two times during case development, maybe have
had influenced mycobacterial dissemination and multi-
focal IRIS presentation.
Given the current WHO policy of test and treat with
earlier ART initiation [14], incidence of IRIS may de-
crease as individuals will be treated earlier and with
higher CD4+ T-cell counts. This case demonstrates the
intricate challenges in managing of highly immunosup-
pressed patients with TB-HIV co-infection at the time of
ART commencement, and emphasizes discussion about
several relevant aspects presented here, such as: (i) risks
associated with ART interruption during ATT in the
context of advanced HIV disease, (ii) the potential hep-
atotoxicity of combined ATT and ART therapy and (iii)
reduced penetration of the drugs in organs/tissues and
its potential association with occurrence of IRIS. These
discussions call attention of the clinical community to
the several nuances in IRIS management.
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